RiethPharma
ActiveSummary
RiethPharma has been active since 2010 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €68,481 and a net result of €9,947. Equity is shrinking by about 15% per year across the filed financial years. Its solvency ranks better than 63% of 12,464 sector peers (NACE 47, financial year 2025). The computed 12-month bankruptcy probability is 0.3% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
04-08
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format · 4 days late
2025
31-12
Financial
Back to profitnet €9,947
Net result €9,947 after 3 loss-making years.
15-07
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
23-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
29-08
NBB filing
Annual accounts filed
financial year 2022 · micro format · 29 days late
2022
31-12
Financial
Weakest financial yearnet -€12,973
Net result drops to -€12,973, the lowest in the series; recovery starts the following year.
29-08
NBB filing
Annual accounts filed
financial year 2021 · micro format · 29 days late
2021
26-07
NBB filing
Annual accounts filed
financial year 2020 · micro format
2020
31-12
Financial
Highest result from 2018 to 2025net €39,734 ▲60.2%
Operating result €58,940, net result €39,734, both a record.
22-07
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
31-07
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
31-07
NBB filing
Annual accounts filed
financial year 2017 · micro format
2017
20-07
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 15 annual accounts filed, the latest 10 are here; all 15 are under Financials.
0 of 3 deeds read
About the unread acts
We know of 3 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.